Clinical Utility of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin

References

• . International Diabetes Federation. IDF Diabetes Atlas, fifth edition. Foreword, http://www.idf.org/diabetesatlas/5e/foreword. Accessed June 15, 2012
   Google Scholar
• . Centers for Disease Control and Prevention. National diabetes fact sheet, 2011. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed August 6, 2012
   Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes—2012. Diabetes Care. 2012;35( suppl 1):S11–S63
   PubMed Web of Science ®Google Scholar
• . Rodbard HW, Jellinger PS, Davidson JA, . Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540–559
   PubMed Web of Science ®Google Scholar
• . Rydén L, Standl E, Bartnik M, ; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28(1):88–136
   PubMed Web of Science ®Google Scholar
• . Inzucchi SE, Bergenstal RM, Buse JB, ; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379
   PubMed Web of Science ®Google Scholar
• . Garber AJ. Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus. J Am Osteopath Assoc. 2011;111(7 suppl 5):S20–S30
   Google Scholar
• . Tradjenta (linagliptin) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2012
   Google Scholar
• . Tradjenta (linagliptin) [package insert]. London, UK: European Medicines Agency; 2012
   Google Scholar
• . KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(2 suppl 2):S12–S154
   PubMed Web of Science ®Google Scholar
• . Moen MF, Zhan M, Hsu VD, . Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1121–1127
   PubMed Web of Science ®Google Scholar
• . Barnett AH. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy. Adv Ther. 2011;28(6):447–459
   PubMed Web of Science ®Google Scholar
• . Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc (2003). 2009;49( suppl 1):S16–S29
   PubMed Web of Science ®Google Scholar
• . Richard KR, Shelburne JS, Kirk JK. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther. 2011;33(11):1609–1629
   PubMed Web of Science ®Google Scholar
• . Ghatak SB, Patel DS, Shanker N, Srivstava A, Deshpande SS, Panchal SJ. Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus. Curr Diabetes Rev. 2010;6(6):410–421
   PubMedGoogle Scholar
• . Yang LP. Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU. Drugs. 2012;72(2):229–248
   PubMed Web of Science ®Google Scholar
• . Kalra S. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes. J Assoc Physicians India. 2011;59:237–245
   PubMedGoogle Scholar
• . Subbarayan S, Kipnes M. Sitagliptin: a review. Expert Opin Pharmacother. 2011;12(10):1613–1622
   PubMed Web of Science ®Google Scholar
• . Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs. 2011;71(11):1441–1467
   PubMed Web of Science ®Google Scholar
• . Deacon CF, Hoist JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2010;19(1):133–140
   PubMed Web of Science ®Google Scholar
• . Fuchs H, Binder R, Greischel A. Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats. Biopharm Drug Dispos. 2009;30(5):229–240
   PubMed Web of Science ®Google Scholar
• . Heise T, Graefe-Mody EU, Hüttner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 2009;11(8):786–794
   PubMed Web of Science ®Google Scholar
• . Graefe-Mody U, Retlich S, Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin Pharmarcokinet. 2012;51(7):411–427
   Google Scholar
• . Kawamori R, Inagaki N, Araki E, . Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab. 2012;14(4):348–357
   PubMed Web of Science ®Google Scholar
• . Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2012;14(6):565–574
   PubMed Web of Science ®Google Scholar
• . Graefe-Mody U, Friedrich C, Port A, . Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*). Diabetes Obes Metab. 2011;13(10):939–946
   PubMed Web of Science ®Google Scholar
• . Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011;13(3):258–267
   PubMed Web of Science ®Google Scholar
• . Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13(7):653–661
   PubMed Web of Science ®Google Scholar
• . Taskinen MR, Rosenstock J, Tamminen I, . Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13(1):65–74
   PubMed Web of Science ®Google Scholar
• . Lewin A, Arvay L, Liu D, Patel S, von Eynatten M, Woerle HJ. Efficacy and safety profile of linagliptin as add-on therapy to sulphonylurea in patients with inadequately controlled type 2 diabetes: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2012;34(9):1909–1919
   PubMed Web of Science ®Google Scholar
• . Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med. 2011;28(11):1352–1361
   PubMed Web of Science ®Google Scholar
• . Yki-Järvinen H, Rosenstock J, Durán-Garcia S, . Long-term safety and efficacy of linagliptin as add-on therapy to basal insulin in patients with type 2 diabetes: a 52-week randomised, placebo-controlled trial. Presented at: 48th European Association for the Study of Diabetes Annual Meeting; October 1–5, 2012; Berlin, Germany
   Google Scholar
• . McGill JB, Sloan L, Newman J, . Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care. 2013;36(2):237–244
   PubMed Web of Science ®Google Scholar
• . Forst T, Pfützner A. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes. Expert Opin Pharmacother. 2012;13(1):101–110
   PubMed Web of Science ®Google Scholar
• . Gallwitz B, Rosenstock J, Rauch T, . 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475–483
   PubMed Web of Science ®Google Scholar
• . Schernthaner G, Barnett AH, Emser A, . Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14(5):470–478
   PubMed Web of Science ®Google Scholar
• . Hüttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol. 2008;48(10):1171–1178
   PubMed Web of Science ®Google Scholar
• . US Department of Health and Human Services; US Food and Drug Administration; Center for Drug Evaluation and Research. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/%20Guidances/UCM071627.pdf. December 2008. Accessed April 2, 2013
   Google Scholar
• . Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol. 2012;11:3
   PubMed Web of Science ®Google Scholar
• . Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005–2012
   PubMed Web of Science ®Google Scholar
• . Gomis R, Owens DR, Taskinen MR, . Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension. Int J Clin Pract. 2012;66(8):731–740
   PubMed Web of Science ®Google Scholar
• . Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther. 2009;31(11):2608–2617
   PubMed Web of Science ®Google Scholar
• . Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos. 2010;38(4):667–678
   PubMed Web of Science ®Google Scholar
• . Graefe-Mody U, Giessmann T, Ring A, Iovino M, Woerle HJ. A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects. Clin Ther. 2011;33(8):1096–1103
   PubMed Web of Science ®Google Scholar
• . Graefe-Mody U, Rose P, Retlich S, . Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br J Clin Pharmacol. 2012;74(1):75–85
   PubMed Web of Science ®Google Scholar
• . Fravel MA, McDanel DL, Ross MB, Moores KG, Starry MJ. Special considerations for treatment of type 2 diabetes mellitus in the elderly. Am J Health Syst Pharm. 2011;68(6):500–509
   PubMed Web of Science ®Google Scholar
• . Neumiller JJ, Setter SM. Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Geriatr Pharmacother. 2009;7(6):324–342
   PubMedGoogle Scholar
• . Abbatecola AM, Maggi S, Paolisso G. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. Drugs Aging. 2008;25(11):913–925
   PubMed Web of Science ®Google Scholar
• . Bourdel-Marchasson I, Schweizer A, Dejager S. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hasp Pract (Minneap). 2011;39(1):7–21
   PubMedGoogle Scholar
• . Schwartz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother. 2010;8(5):405–418
   PubMedGoogle Scholar
• . Barnett A, Huisman H, Jones R, Von Eynatten M, Patel S, Woerle HJ. Efficacy and safety of linagliptin in elderly patients (a 70 years) with type 2 diabetes. Presented at: 9th International Diabetes Federation Western Pacific Region Congress; November 24–27, 2012; Kyoto, Japan
   Google Scholar
• . Shah RR. Pharmacogenetics in drug regulation: promise, potential and pitfalls. Philos Trans R Soc Land B Biol Sci. 2005;360(1460):1617–1638
   PubMed Web of Science ®Google Scholar
• . Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc. 2002;94( 10 suppl):1–26
   PubMed Web of Science ®Google Scholar
• . Forst T, Uhlig-Laske B, Ring A, Ritzhaupt A, Graefe-Mody U, Dugi KA. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13(6):542–550
   PubMed Web of Science ®Google Scholar
• . Horie Y, Kanada S, Watada H, . Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients. Clin Ther. 2011;33(7):973–989
   PubMed Web of Science ®Google Scholar
• . Sarashina A, Sesoko S, Nakashima M, . Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. Clin Ther. 2010;32(6):1188–1204
   PubMed Web of Science ®Google Scholar
• . Friedrich C, Shi X, Zeng P, Ring A, Woerle HJ, Patel S. Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers. Int J Clin Pharmacol Ther. 2012;50(12):889–895
   PubMed Web of Science ®Google Scholar
• . Friedrich C, Glund S, Lionetti D, . Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus [published online ahead of print January 18, 2013]. Br J Clin Pharmacol
   Google Scholar
• . Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet. 2010;49(9):573–588
   PubMed Web of Science ®Google Scholar
• . Graefe-Mody EU, Padula S, Ring A, Withopf B, Dugi KA. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin. 2009;25(8):1963–1972
   PubMed Web of Science ®Google Scholar
• . Graefe-Mody EU, Jungnik A, Ring A, Woerle HJ, Dugi KA. Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers. Int J Clin Pharmacol Ther. 2010;48(10):652–661
   PubMed Web of Science ®Google Scholar
• . Graefe-Mody U, Rose P, Ring A, Zander K, Iovino M, Woerle HJ. Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects. Drug Metab Pharmacokinet. 2011;26(2):123–129
   PubMed Web of Science ®Google Scholar
• . Graefe-Mody U, Huettner S, Stähle H, Ring A, Dugi KA. Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin. Int J Clin Pharmacol Ther. 2010;48(6):367–374
   PubMed Web of Science ®Google Scholar
• . Graefe-Mody EU, Brand T, Ring A, . Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Int J Clin Pharmacol Ther. 2011;49(5):300–310
   PubMed Web of Science ®Google Scholar
• . Friedrich C, Ring A, Brand T, Sennewald R, Graefe-Mody EU, Woerle HJ. Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. Eur J Drug Metab Pharmacokinet. 2011;36(1):17–24
   PubMed Web of Science ®Google Scholar
• . Friedrich C, Port A, Ring A, . Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study. Clin Drug Investig. 2011;31(9):643–653
   PubMed Web of Science ®Google Scholar
• . Anagnostis P, Athyros VG, Adamidou F, . Glucagon-like peptide-1–based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab. 2011;13(4):302–312
   PubMed Web of Science ®Google Scholar
• . Mima A, Hiraoka-Yamomoto J, Li Q, . Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes. Diabetes. 2012;61(11):2967–2979
   PubMed Web of Science ®Google Scholar
• . De Meester I, Durinx C, Bal G, . Natural substrates of dipeptidyl peptidase IV. In: Langner J, Ansorge S, eds. Cellular Peptidases in Immune Functions and Diseases 2. Vol 477. New York, NY: Springer US; 2002:67–87
   Google Scholar
• . Brandt I, Lambeir AM, Maes MB, Scharpé S, De Meester I. Peptide substrates of dipeptidyl peptidases. In: Lendeckel U, Reinhold D, Bank U, eds. Dipeptidyl Aminopeptidases. Vol 575. New York, NY: Springer US; 2006:3–18
   Google Scholar
• . Groop PH, Cooper M, Perkovic V, Emser A, Von Eynatten M, Woerle HJ. Linagliptin lowers albuminuria on top of recommended standard treatment for diabetic nephropathy. Presented at: 72nd American Diabetes Association Scientific Sessions; June 8–12, 2012; Philadelphia, PA. Abstract 953-P
   Google Scholar
• . Scott LJ, Lyseng-Williamson KA. Linagliptin: a guide to its use in type 2 diabetes mellitus. Drugs Ther Per sped. 2012;28(5):1–5
   Google Scholar